Physician profile
David Fletcher
NPI 1548461643
$10,544.98
in general payments reported to CMS, 2019-2025
50 companies · $832 in 2025
The $832 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,328 · 2020: $2,191 · 2021: $1,060 · 2022: $1,022 · 2023: $1,067 · 2024: $1,045 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,742.38 | 2019-2025 | |
| Novo Nordisk INC | $944.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $808.71 | 2019-2025 | |
| Shield Therapeutics INC | $755.88 | 2023-2024 | Accrufer |
| Lilly USA, LLC | $518.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $320.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $284.99 | 2021-2025 | |
| Amarin Pharma, INC. | $278.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $208.79 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $191.38 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.54 | 2019-2025 | Trintellix |
| Amgen INC. | $176.67 | 2019-2023 | Otezla, Repatha |
| Allergan, INC. | $166.42 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $154.75 | 2020-2023 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.59 | 2019-2024 | Xifaxan |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.